FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).

Catenacci, Daniel V. T.; Kang, Yoon-Koo; Saeed, Anwaar; Yamaguchi, Kensei; Qin, Shukui; Lee, Keun-Wook; Kim, In-Ho; Oh, Sang Cheul; Li, Jin; Turk, Haci M.; Teixeira, Alexandra Carolina; Borg, Christophe; Hitre, Erika; Udrea, Anghel Adrian; Cardellino, Giovanni Gerardo; Guardeno, Raquel; Mitra, Siddhartha; Yang, Yingsi; Enzinger, Peter C.; Wainberg, Zev A.

Publication:
FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).

dc.contributor.author	Catenacci, Daniel V. T.
dc.contributor.author	Kang, Yoon-Koo
dc.contributor.author	Saeed, Anwaar
dc.contributor.author	Yamaguchi, Kensei
dc.contributor.author	Qin, Shukui
dc.contributor.author	Lee, Keun-Wook
dc.contributor.author	Kim, In-Ho
dc.contributor.author	Oh, Sang Cheul
dc.contributor.author	Li, Jin
dc.contributor.author	Turk, Haci M.
dc.contributor.author	Teixeira, Alexandra Carolina
dc.contributor.author	Borg, Christophe
dc.contributor.author	Hitre, Erika
dc.contributor.author	Udrea, Anghel Adrian
dc.contributor.author	Cardellino, Giovanni Gerardo
dc.contributor.author	Guardeno, Raquel
dc.contributor.author	Mitra, Siddhartha
dc.contributor.author	Yang, Yingsi
dc.contributor.author	Enzinger, Peter C.
dc.contributor.author	Wainberg, Zev A.
dc.date.accessioned	2021-11-30T20:59:13Z
dc.date.available	2021-11-30T20:59:13Z
dc.date.issued	2021-05-01T00:00:00Z
dc.identifier.citation	Catenacci D. V. T. , Kang Y., Saeed A., Yamaguchi K., Qin S., Lee K., Kim I., Oh S. C. , Li J., Turk H. M. , et al., -FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021
dc.identifier.doi	10.1200/jco.2021.39.15_suppl.4010
dc.identifier.uri	http://hdl.handle.net/20.500.12645/29666
dc.identifier.wos	WOS:000708120602112
dc.title	FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).
dc.type	Article
dspace.entity.type	Publication
local.avesis.id	09ff4e89-ff5b-4ecc-ac8d-a5abb22be087
local.indexed.at	WOS
local.publication.isinternational	1

Collections

Yayınlar - Eserler

Publication: FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).

Files

Collections

Publication:
FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).